INCY
Incyte Corp.

5,538
Mkt Cap
$18.98B
Volume
2.46M
52W High
$109.28
52W Low
$53.56
PE Ratio
16.22
INCY Fundamentals
Price
$95.16
Prev Close
$96.70
Open
$96.52
50D MA
$95.74
Beta
0.50
Avg. Volume
2.35M
EPS (Annual)
$0.1549
P/B
4.08
Rev/Employee
$1.62M
Loading...
Loading...
News
all
press releases
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
The Investment Committee debate the latest Calls of the Day...
CNBC Television-YouTube·4h ago
News Placeholder
More News
News Placeholder
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
The Investment Committee debate the latest Calls of the Day...
CNBC Television-YouTube·4h ago
News Placeholder
Calls of the Day: Netflix, Thermo Fisher, Incyte and Shake Shack
The Investment Committee debate the latest Calls of the Day...
CNBC Television-YouTube·4h ago
News Placeholder
Incyte (NASDAQ:INCY) Stock Rating Upgraded by Mizuho
Mizuho upgraded Incyte from a "hold" rating to a "strong-buy" rating and increased their price target for the stock from $90.00 to $121.00 in a research report on Monday...
MarketBeat·9h ago
News Placeholder
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin...
Business Wire·1d ago
News Placeholder
Incyte (NASDAQ:INCY) Trading Down 6.6% - Should You Sell?
Incyte (NASDAQ:INCY) Stock Price Down 6.6% - Here's What Happened...
MarketBeat·1d ago
News Placeholder
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Zacks·1d ago
News Placeholder
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Zacks·1d ago
News Placeholder
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Zacks·1d ago
News Placeholder
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
Zacks·1d ago

Latest INCY News

View

Advertisement|Remove ads.

Advertisement|Remove ads.